SECreport
Form 4 CASI Pharmaceuticals, For: Sep 28 Filed by: Chi George
Last casi pharmaceuticals, inc earnings: 11/14 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations: casipharmaceuticals.com/investor-relations
| IMPACT SNAPSHOT | EVENT TIME: | CASI | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
CASI alerts
CASI alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CASI alerts
High impacting CASI Pharmaceuticals, Inc news events
Weekly update
A roundup of the hottest topics
CASI
NEWS
NEWS
- CASI Pharmaceuticals To Present At The 2019 BIO International Convention[PR Newswire]
- CASI Pharmaceuticals Inc (NASDAQ: CASI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.[MarketBeat]
- CASI Pharmaceuticals Announces First Quarter 2019 Financial and Business Results[PR Newswire]
- CASI Pharmaceuticals In-Licenses Exclusive Worldwide Rights to Novel Anti-CD38 Monoclonal Antibody Program From Black Belt Therapeutics[PR Newswire]
- CASI Pharmaceuticals Inc (NASDAQ: CASI) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating.[MarketBeat]
- More
CASI
SEC Filings
SEC Filings
- 6/6/19 - Form CT
- 5/15/19 - Form 10-Q
- 5/15/19 - Form 8-K
- CASI's page on the SEC website
- More